In the absence of definitive gene expression profiling, molecular subtype can be assigned using clinicopathologic elements such as her2/neu (HER2), expression, tumour grade, and the expression of hormone receptor status including estrogen (ER) and progesterone receptors (PR) [2,3]. The gene discussed is ERBB2; the disease is neoplasm.